10-Q: Sera Prognostics Reports Q2 2025 Results

Sera Prognostics, a women's health company, reported a reduced net loss in Q2 2025, bolstered by a recent $53.6M capital raise and positive clinical trial data for its PreTRM test.

Summary

• Sera Prognostics, Inc. is a women's health company focused on blood-based biomarker tests and predictive analytics, primarily its PreTRM test for preterm birth risk.
• The company reported a net loss of $8.046 million for the three months ended June 30, 2025, an improvement from $8.303 million in the same period of 2024.
• For the six months ended June 30, 2025, the net loss was $16.233 million, down from $16.400 million in the prior year period.
• Revenue for Q2 2025 was $17 thousand, a decrease from $24 thousand in Q2 2024, while six-month revenue increased to $55 thousand from $24 thousand.
• Cash, cash equivalents, and marketable securities significantly increased to $108.511 million as of June 30, 2025, up from $68.209 million at December 31, 2024.
• The increase in liquidity was primarily driven by $53.6 million in net proceeds from an underwritten public offering completed in February 2025.
• Net cash used in operating activities for the six months ended June 30, 2025, was $13.026 million, a substantial increase from $0.934 million in the prior year period.
• The company's PreTRM test is the only broadly validated, commercially available blood-based biomarker test to accurately predict preterm birth risk.
• Positive results from the AVERT PRETERM TRIAL (published July 2024) showed an 18% reduction in severe neonatal morbidity and mortality and a 7-day reduction in mean neonatal hospital length of stay.
• Key results from the PRIME study (presented January 2025) indicated a 25% reduction in neonatal morbidity and mortality and an 18% reduction in neonatal hospital length of stay in the mITT population, and a 20% reduction in both in the ITT population.
• A pooled meta-analysis of AVERT and PRIME studies demonstrated a 22% decreased risk of prolonged hospital stay and a 22% reduction in neonatal morbidity and mortality.
• The company is expanding its commercial team, including hiring a Chief Commercial Officer in Q2 2025 and field sales representatives in Q3 2025, focusing on strategic geographies.
• Sera Prognostics believes its existing cash and cash equivalents will fund operations through 2028.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company continues to incur significant losses and has very low revenue, the successful capital raise has significantly improved its liquidity and extended its cash runway through 2028. The strong positive clinical trial results for its lead product, PreTRM, and the strategic expansion of its commercial team indicate progress towards market adoption. The vacating of the FDA's LDT rule also removes an immediate regulatory hurdle. However, the increased cash burn from operations and the early stage of commercialization temper the overall positive outlook, reflecting continued high risk.

Positives

• Net loss decreased for both the three and six months ended June 30, 2025, compared to the prior year periods, indicating improved financial performance in terms of loss reduction.
• Total cash, cash equivalents, and marketable securities increased significantly to $108.511 million as of June 30, 2025, providing a strong liquidity position.
• The company successfully completed an underwritten public offering in February 2025, raising approximately $53.6 million in net proceeds, extending its cash runway through 2028.
• The PreTRM test is the only broadly validated, commercially available blood-based biomarker test for preterm birth risk, offering a unique market position.
• Positive clinical trial results from the AVERT PRETERM TRIAL and PRIME study demonstrate significant reductions in neonatal morbidity and mortality (18-25%) and hospital length of stay (7-18 days), supporting the test's clinical utility.
• Pooled meta-analysis of AVERT and PRIME studies shows a 22% decreased risk of prolonged hospital stay and a 22% reduction in neonatal morbidity and mortality, strengthening the evidence base.
• Health economic data suggests a low Number Needed to Screen (NNS) for PreTRM to save a NICU day (3-4) and 41 to save a NICU admission, significantly better than standard care (150 NNS for NICU admission), presenting a strong value proposition to payers.
• The company is actively expanding its commercial team and focusing on strategic geographies to drive market adoption.
• A federal district court judge vacated the FDA's final rule on LDTs in March 2025, reducing immediate regulatory burden on the company's PreTRM test.

Negatives

• Revenue remains very low at $17 thousand for the three months ended June 30, 2025, indicating limited commercial traction despite positive clinical data.
• Net cash used in operating activities for the six months ended June 30, 2025, significantly increased to $13.026 million from $0.934 million in the prior year, indicating a higher cash burn rate.
• The company continues to incur significant operating losses and negative cash flows, with an accumulated deficit of $296.027 million as of June 30, 2025.
• Increased selling and marketing expenses ($0.7 million increase for Q2 2025 vs Q2 2024) and general and administrative expenses ($0.4 million increase for Q2 2025 vs Q2 2024) contribute to the ongoing cash burn.
• The company expects it may take a few quarters for new sales representatives to achieve significant adoption and a favorable return on commercial investment.

Risks

• Continued net losses and negative cash flows are anticipated for the foreseeable future, potentially harming future business prospects.
• The company requires significant cash for operations and may need to raise additional capital, which may not be available on satisfactory terms or at all, potentially leading to curtailment or cessation of operations.
• Quarterly and annual results may fluctuate significantly due to various factors, including competitive pricing, reimbursement pressures, and supply chain disruptions.
• Substantial reliance on the PreTRM test for revenue; failure to increase its use and adoption or develop new products will harm the business.
• Customer concentration risk, particularly with Elevance Health, where loss of relationship could adversely impact commercialization strategy.
• Inability to establish and maintain effective sales and marketing capabilities could hinder successful commercialization.
• Intense competition in the life science industry, especially in molecular diagnostics and proteomics, from companies with greater resources.
• Risk of the CLIA-certified laboratory facility becoming inoperable due to disasters or other events, leading to inability to perform tests.
• Potential for substantial damages from product liability or professional liability claims if tests fail to perform as designed or results are misinterpreted.
• Clinical trial results may not support the use of tests or be replicated in later studies, impairing adoption.
• Risk of proprietary biobank becoming contaminated, lost, or destroyed, materially harming business.
• Reliance on access to internal and external databases; loss of access could harm business.
• International expansion exposes the company to business, regulatory, political, operational, financial, and economic risks.
• Reliance on third parties for specimen collection and courier delivery services; disruptions could harm business.
• Reliance on a limited number of suppliers for laboratory instruments, materials, and collection kits; inability to find replacements could cause delays or increased costs.
• Ability to utilize net operating loss carryforwards and other tax attributes may be limited by ownership changes.
• Estimates of total addressable market opportunity and growth forecasts may be inaccurate.
• An inflationary environment and unstable global economic/geopolitical conditions could materially adversely impact business and results of operations.
• Inadequate funding for SEC and other government agencies could hinder their ability to perform normal business functions, impacting the company.
• Third-party payers may not adequately reimburse for the PreTRM test or future tests, or may decrease reimbursement rates, affecting revenue and profits.
• Billing disputes with third-party payers, including CPT code disagreements, may decrease realized revenue and lead to recoupment requests.
• Inability to collect from patients when third-party payers deny coverage.
• Out-of-network provider status with large commercial insurers may deter healthcare providers from recommending tests.
• Changes in government healthcare policy could increase costs and negatively impact coverage and reimbursement.
• Challenges to the validity of informed consent from patients could preclude billing or force cessation of testing.
• Changes in FDA regulation of reagents, consumables, and testing equipment could result in delays or additional expense.
• Failure to comply with federal and/or state laboratory licensing requirements could lead to loss of ability to perform tests.
• Failure to obtain, maintain, and enforce intellectual property rights could impair protection of proprietary technology and brand.
• Issued patents covering tests and technology could be found invalid or unenforceable if challenged.
• Intellectual property may be infringed by third parties, leading to costly and time-consuming litigation.
• Inability to prevent disclosure of trade secrets and other proprietary information could diminish the value of tests and technology.
• The price of Class A common stock may be volatile, and investors could lose all or part of their investment.
• Sales of a substantial number of shares by existing stockholders could cause stock price to decline.
• Anti-takeover provisions in charter documents and Delaware law could delay or prevent a change in control.
• Reduced reporting requirements as an emerging growth company (EGC) and smaller reporting company may make Class A common stock less attractive to investors.
• Inability to maintain effective disclosure controls and procedures could adversely affect financial results and stock price.
• Significant costs of operating as a public company and management time devoted to compliance initiatives.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reports or fraud.
• Artificial intelligence presents risks including security risks to confidential information and challenges from an uncertain and evolving regulatory environment.

Future Outlook

The company expects to incur significant additional operating losses and negative cash flows for the foreseeable future due to commercialization activities for the PreTRM test and development of other pipeline products. It anticipates increasing research and development expenses in the second half of 2025 due to increased product development and planned studies, and selling and marketing expenses will also increase. The company believes its existing cash and cash equivalents are sufficient to fund operating expenses and capital expenditure requirements through 2028. Future funding requirements depend on achieving broad commercial success, regulatory approvals, and managing costs of clinical studies and intellectual property.

Management Comments

• We believe that our method of combining the disciplines of proteomics and bioinformatics with rigorous clinical testing, data, and economic analysis enables us to provide physicians and expectant mothers with personally insightful, clinically meaningful, and economically impactful information designed to improve the pregnancy experience and outcomes for mothers and babies.
• We believe the substantial health benefits of this model translate very favorably to health economic savings, creating a powerful value proposition to insurance payers.
• We are currently seeking publication of full PRIME data, which includes these and other study results, in a highly respected, peer-reviewed journal, and we expect to generate additional publications on exploratory analyses and economic benefits in the coming months.
• We believe market adoption by both health care providers and payers should be aided by the publications of our AVERT PRETERM TRIAL, PRIME study, and forthcoming real-world evidence studies.
• We expect that it may take a few quarters for each new sales representative to begin seeing significant density of adoption of this novel diagnostic test within their territory and and to provide a favorable return on our commercial investment in such territories.
• We significantly reduced our annual operating expenses across all aspects of our business over the past 24 months and will continue to prudently monitor our operating expense levels.
• We believe our cash runway is sufficient to enable us to operate through 2028 based on our existing operating plans.

Industry Context

Sera Prognostics operates in the rapidly evolving women's health diagnostics sector, specifically leveraging proteomics and bioinformatics for maternal and neonatal health. The focus on preterm birth addresses a major health risk and economic burden in the U.S. healthcare system, as highlighted by the March of Dimes' D+ grade for the nation's preterm birth rate. The company's strategy aligns with the American College of Obstetricians and Gynecologists' (ACOG) emphasis on risk assessments in prenatal care, positioning its PreTRM test as a tool to direct interventions and resources. The vacating of the FDA's LDT rule provides a temporary reprieve from immediate regulatory burdens, which is favorable for companies in this space. However, the industry faces intense competition, reimbursement challenges, and evolving regulatory landscapes, including potential future legislative efforts for LDT oversight.

Comparison to Industry Standards

• The company's PreTRM test boasts a Number Needed to Screen (NNS) of 3-4 to save a NICU day and 41 to save a NICU admission. This compares favorably to the standard of care for short cervix (transvaginal ultrasound plus progesterone treatments), which has an NNS of 150 to save a NICU admission, indicating a potentially more efficient and cost-effective intervention strategy.
• While specific comparable companies or projects are not detailed with numerical results for direct comparison, the filing emphasizes the PreTRM test as the 'only broadly validated, commercially available blood-based biomarker test to accurately predict the risk of a preterm birth,' suggesting a leading position in this specific niche.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material litigation or other material legal proceedings.

Related Party Transactions

• The company has a Commercial Collaboration Agreement with Elevance Health and its affiliates, which provides defined payment for the use of the PreTRM test within Elevance Health's network.
• Entities affiliated with one of the company's principal stockholders purchased 11,250,000 pre-funded warrants in the February 2025 public offering at $3.9999 per warrant.
• Another principal stockholder purchased 625,000 shares of Class A common stock in the February 2025 public offering at $4.00 per share.
• The company paid Carelon Research (a subsidiary of Elevance Health) $0.4 million for the six months ended June 30, 2025, for research projects, including the PRIME study.

Stakeholder Impact

• **Shareholders**: The recent capital raise significantly improved liquidity and extended the cash runway, reducing immediate dilution risk but future capital raises may still dilute. The stock price remains volatile, and anti-takeover provisions limit shareholder influence. Positive clinical data could drive long-term value.
• **Employees**: Strategic headcount reductions have occurred, potentially impacting morale and institutional knowledge. New hires in commercial roles indicate growth opportunities. Stock-based compensation is a significant component of employee compensation.
• **Customers (Healthcare Providers & Patients)**: The PreTRM test offers a novel, validated solution for preterm birth risk prediction, potentially improving maternal and neonatal health outcomes. Expanded commercial efforts aim to improve test accessibility and adoption.
• **Payers**: Strong health economic data (low NNS) provides a compelling value proposition for insurance payers, potentially leading to broader coverage and reimbursement for the PreTRM test.
• **Suppliers**: Reliance on a limited number of suppliers for critical components and services poses supply chain risks, which could impact test performance and availability.

Next Steps

• Seek publication of full PRIME study data in a highly respected, peer-reviewed journal.
• Generate additional publications on exploratory analyses and economic benefits of the PreTRM test in the coming months.
• Integrate data from studies into a health economic model to be made available to prospective customers.
• Complete the qualitative pre-implementation phase of the first real-world evidence implementation program.
• Continue expanding the commercial team, including hiring field sales representatives in strategic geographies in Q3 2025.
• Evaluate the allocation of resources to accelerate market adoption of the PreTRM test and develop/launch additional pipeline products.
• Continue to pursue contracts with private and governmental payers and health systems.
• Continue early market testing of the new test designed to provide a more accurate estimate of the delivery date for expectant mothers.

Key Dates

Recommendation

Sera Prognostics presents a high-risk, high-reward investment profile. The company has significantly bolstered its liquidity with a recent $53.6 million capital raise, extending its cash runway through 2028, which is crucial given its ongoing substantial operating losses and minimal revenue. The positive clinical trial results for the PreTRM test are compelling, demonstrating significant improvements in neonatal outcomes and favorable health economics compared to standard care. This strong clinical evidence provides a solid foundation for future commercialization. However, the company is still in the very early stages of commercial adoption, with revenue remaining extremely low and a notable increase in cash burn from operations. The success of its commercial expansion and ability to secure widespread payer reimbursement are highly uncertain and will take time to materialize. For existing investors, holding the stock allows for observation of commercial progress and further clinical data publications, supported by the extended cash runway. For new investors, the speculative nature of the business, high cash burn, and unproven commercial model warrant caution, making it a 'hold' until clearer signs of revenue growth and sustainable operations emerge.

Keywords

PreTRM test, Preterm birth, Proteomics, Bioinformatics, Maternal health, Neonatal health, Biomarker tests, Diagnostic tests, SEC filing, 10-Q, Clinical trials, Healthcare diagnostics, Medical technology, Women's health